Briefing

IonQ’s acquisition of Capella Space signals a bold convergence of quantum computing and orbital infrastructure, marrying the deep precision of quantum key distribution (QKD) with the persistent presence and data collection capabilities of Earth-observing satellites. The closing of the deal sets in motion IonQ’s ambitious plan to develop a space-to-space and space-to-ground QKD … [Read more...] about IonQ Acquires Capella Space to Launch Quantum-Secure Satellite Network

Crypto Week on Capitol Hill nearly unraveled before it began. Aiming to showcase Republican unity and deliver major legislative wins for the digital asset industry, GOP leaders designated this week as a milestone for cryptocurrency policy. But early on July 15, the effort faltered when a procedural vote failed in the House of Representatives. Thirteen Republicans joined … [Read more...] about Trump’s Intervention Rescues Crypto Week After House Setback

With Nvidia now brushing against a $4 trillion market cap and dominating headlines as the poster child of the AI boom, investors are rapidly turning their attention to the next big mover—AMD. The company, long seen as a tenacious underdog, is now stepping confidently into a new era of growth that could propel it to a $1 trillion valuation far sooner than many expect. Currently … [Read more...] about AMD Eyes the Trillion-Dollar Club as AI Momentum Accelerates

Shares of Visa, Mastercard, and American Express are losing ground today as mounting concerns over global trade tensions and tariff policy reverberate through financial markets. With the White House escalating rhetoric on import levies—floating the possibility of sweeping new tariffs on European and Mexican goods—investors are taking a more cautious stance on consumer-facing … [Read more...] about Tariff Turbulence Rattles Markets: Visa, Mastercard, and American Express Slide Amid Trade Uncertainty

Beam Therapeutics (NASDAQ: BEAM), currently trading around $20, may seem like just another early-stage biotech firm navigating the turbulent seas of clinical research. But beneath that modest share price lies a well-capitalized company, armed with cutting-edge base editing technology, deep clinical programs, and the potential for multiple catalysts that could propel its stock … [Read more...] about Beam Therapeutics: Why Shares Could Surge to $80